The Lancet Psychiatry
Fecha de publicación: July 2018
DOI: https://doi.org/10.1016/S2215-0366(18)30178-0
Autores: Tomislav Franić, Katarina Dodig Ćurković.
Background: In a recent letter, John Hayden and colleagues responded to a Review by Kapil Sayal and colleague on the prevalence of attention-deficit hyperactivity disorder (ADHD) in children and young people, and the related care pathways and service provision. Commendably, Hayden and colleagues gave examples of country-specific barriers to accessing ADHD medications, and also stated that “in other European countries such as Croatia, due to potential economic burden, psychostimulants for treatment of ADHD are not available to public patients.
